The Parkinson Voice Project (PVP) has awarded a specialized training grant to the speech-language pathology program at Yeshiva University in New York that will enable graduate students to offer virtual SPEAK OUT! voice therapy to people living with Parkinson’s disease. SPEAK OUT! is a research-backed therapy program…
News
1ST Biotherapeutics said it joined an initiative led by the Michael J. Fox Foundation (MJFF) aimed at advancing therapies that target the LRRK2 gene, a key genetic contributor to Parkinson’s disease. The initiative, MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program, brings together biotech companies and academic research…
A case study of 10 people who experienced tics in childhood and developed Parkinson’s disease as adults illustrates how the underlying mechanisms of both disorders might be more complex than hypothesized. Researchers looked at individuals whose tics continued after the onset of Parkinson’s symptoms and treatment. Most…
Two undergraduate students from Rice University in Houston have designed an affordable, vibrating glove that they say lets patients feel vibrations in their fingertips to retrain misfiring neurons (nerve cells) in the brain — a hallmark of Parkinson’s disease — and help them regain motor control. The work by…
The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for XS-411, a stem cell-based therapy developed by Xellsmart for Parkinson’s disease, clearing the way for a Phase 1 clinical trial. The company also received FDA approval for a similar stem cell therapy…
Nearly 1 in 8 people diagnosed with Parkinson’s disease in Finland within the past couple of decades were later given a different diagnosis, usually within two years, underscoring the need for better clinical criteria and regular checkups. When Parkinson’s and dementia with Lewy bodies, a neurodegenerative disease also…
Scientists have developed a blood test to detect Parkinson’s disease in its very early stages, before a person experiences the first symptoms that would normally prompt a Parkinson’s diagnosis, a study showed. After identifying that people with Parkinson’s have alterations in two types of transfer RNA fragments (tRFs),…
The Van Andel Institute (VAI) — founded nearly three decades ago to advance biomedical research and science education — is awarding its 2025 Jay Van Andel Award to a University of Pittsburgh professor for his work on environmental factors in Parkinson’s disease. This year’s award will be presented…
Suppressing the immune system to reduce brain inflammation, a known contributor to Parkinson’s disease progression, may offer a promising new strategy for slowing the disease, early trial results suggest. Specifically, azathioprine, a commonly used drug that suppresses immune activity, reduced motor symptoms and improved cognitive function in people…
The investigational liquid therapy ND0612 — an around-the-clock supply of levodopa/carbidopa infused via a pump under the skin — provides more stable motor control in people with Parkinson’s disease who experience motor fluctuations than standard immediate-release levodopa/carbidopa. That’s according to data from the randomized portion of the…
Recent Posts
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s
- Trial testing Crexont for advanced Parkinson’s kicks off in Europe